Semaglutide

Semaglutide in the ESSENCE Trial: A Breakthrough for Liver Disease Treatment?

by
Semaglutide in the ESSENCE Trial: A Breakthrough for Liver Disease Treatment?

Liver disease, especially metabolic dysfunction-associated steatohepatitis (MASH), has long been a silent threat, affecting millions of people globally. Often progressing unnoticed until advanced stages, MASH—formerly known as nonalcoholic steatohepatitis (NASH)—can lead to liver fibrosis, cirrhosis, and even liver failure. For years, patients and physicians alike have faced a harsh reality: there are virtually no approved … Read more

Sharing is Caring
Share

Weight-Loss Jabs Could Slash Cancer Risk by 50%: A “Transformational” Breakthrough

by
Weight-Loss Jabs

Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress on Obesity 2025 and published in The Lancet’s eClinicalMedicine) analyzed 6,000 adults with obesity but no prior cancer. Two Groups Compared: Surprising Results Lead author Prof. Dror Dicker (Israel):“Newer GLP-1 drugs like Mounjaro may be even more powerful … Read more

Sharing is Caring
Share

Tirzepatide vs. Semaglutide for Obesity: Which Weight-Loss Drug Works Better?

by
Tirzepatide vs. Semaglutide for Obesity: Which Weight-Loss Drug Works Better?

New SURMOUNT-5 Trial Results (2025) Key Takeaways ✅ Tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy). Background: The Rise of GLP-1 Drugs for Obesity Obesity is a chronic disease linked to heart disease, diabetes, and early death. For years, lifestyle changes alone weren’t enough for many people to achieve lasting weight loss. Then came GLP-1 receptor … Read more

Sharing is Caring
Share

Frequent Asked Questions about Obesity

by
Frequent Asked Questions about Obesity

Obesity is one of the most misunderstood health crises of our time. Below, we tackle the most pressing questions—backed by science, not stigma. 1. “Is Obesity Really a Disease, or Just a Lack of Willpower?” Expert Insight:The American Medical Association (AMA) classified obesity as a chronic disease in 2013. Why? Because: Takeaway: Blaming willpower ignores science. Obesity is … Read more

Sharing is Caring
Share

The Paradox of Obesity Drugs: How Opposite Approaches Both Lead to Weight Loss

by
The Paradox of Obesity Drugs: How Opposite Approaches Both Lead to Weight Loss

A Scientific Mystery Solved In a breakthrough that defies conventional logic, researchers have discovered that two completely opposite drug strategies—stimulating and blocking the same hormone receptor—both effectively promote weight loss, but through entirely different brain mechanisms. This surprising finding, published in Nature Metabolism, could revolutionize how we develop future obesity treatments. The GIP Paradox: Opposing Actions, Same Result The study … Read more

Sharing is Caring
Share

List of Oral GLP-1 Drugs: 2025 Update

by
Tirzepatide vs. Semaglutide for Obesity: Which Weight-Loss Drug Works Better?

With GLP-1 receptor agonists (GLP-1 RAs) gaining popularity for managing type 2 diabetes and promoting weight loss, many people are looking for oral (non-injection) options. While most GLP-1 drugs are injectable, there is one FDA-approved oral GLP-1 drug currently available. Oral GLP-1 Drugs List 1. Semaglutide (Brand Name: Rybelsus) Rybelsus is the first and only … Read more

Sharing is Caring
Share

WHO Supports Worldwide Use of Adult Weight-Loss Drugs, Highlights Cost Hurdle

by
WHO Set to Endorse Weight-Loss Drugs for Global Obesity Treatment, Highlights Cost Barriers

In a groundbreaking move, the World Health Organization (WHO) is preparing to recommend the use of weight-loss medications like Wegovy and Zepbound to manage obesity in adults — a first in its global public health strategy. According to a WHO memo obtained by Reuters, this decision marks a major policy shift and highlights the growing … Read more

Sharing is Caring
Share